Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares

Core Viewpoint - Genenta Science has entered into a securities purchase agreement to sell 4,285,715 American Depositary Shares (ADSs) at $3.50 per ADS, aiming for gross proceeds of approximately $15.0 million before expenses [1][2]. Group 1: Offering Details - The offering involves the sale of securities solely by Genenta, with no warrants or derivative securities issued [1]. - Maxim Group LLC is the lead placement agent, while Rodman & Renshaw LLC acts as the co-placement agent for the offering [2]. - The expected closing date for the offering is around October 28, 2025, pending customary closing conditions [2]. Group 2: Use of Proceeds - Genenta plans to utilize the net proceeds from the offering for working capital and general corporate purposes [2]. Group 3: Company Overview - Genenta Science is a clinical-stage immuno-oncology company focused on developing proprietary hematopoietic stem cell therapies for solid tumor cancers [5]. - The company's lead product candidate, Temferon™, aims to express immune-therapeutic payloads within the tumor microenvironment, potentially enhancing immune responses [5]. - Genenta has completed a Phase 1 trial for newly diagnosed Glioblastoma Multiforme (GBM) patients and has initiated a Phase 1/2a study for metastatic Renal Cell Carcinoma, which will include combinations with immune checkpoint inhibitors [5].